WO2002047537A3 - Compositions and methods for in situ and in vivo imaging of cells and tissues - Google Patents

Compositions and methods for in situ and in vivo imaging of cells and tissues Download PDF

Info

Publication number
WO2002047537A3
WO2002047537A3 PCT/US2001/048157 US0148157W WO0247537A3 WO 2002047537 A3 WO2002047537 A3 WO 2002047537A3 US 0148157 W US0148157 W US 0148157W WO 0247537 A3 WO0247537 A3 WO 0247537A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tissues
cells
compositions
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/048157
Other languages
French (fr)
Other versions
WO2002047537A2 (en
Inventor
Arul M Chinnaiyan
Alnawaz Rehemtulla
Brian D Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Priority to AU2002232568A priority Critical patent/AU2002232568A1/en
Priority to EP01992094A priority patent/EP1501476A2/en
Publication of WO2002047537A2 publication Critical patent/WO2002047537A2/en
Anticipated expiration legal-status Critical
Publication of WO2002047537A3 publication Critical patent/WO2002047537A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The invention provides compositions and methods for imaging cells and tissues in vivo and in situ. Compositions and methods are provided for administration to enhance the imaging of cells and tissues by, e.g., computer assisted tomography (CAT), magnetic resonance spectroscopy (MRS), magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), or bioluminescence imaging (BLI). Thus, the invention provides compositions and methods for identifying sites of primary and metastatic tumors and tumor neovasculature.
PCT/US2001/048157 2000-12-11 2001-12-11 Compositions and methods for in situ and in vivo imaging of cells and tissues Ceased WO2002047537A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002232568A AU2002232568A1 (en) 2000-12-11 2001-12-11 Compositions and methods for in situ and in vivo imaging of cells and tissues
EP01992094A EP1501476A2 (en) 2000-12-11 2001-12-11 Compositions and methods for in situ and in vivo imaging of cells and tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73462800A 2000-12-11 2000-12-11
US09/734,628 2000-12-11

Publications (2)

Publication Number Publication Date
WO2002047537A2 WO2002047537A2 (en) 2002-06-20
WO2002047537A3 true WO2002047537A3 (en) 2004-11-25

Family

ID=24952460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048157 Ceased WO2002047537A2 (en) 2000-12-11 2001-12-11 Compositions and methods for in situ and in vivo imaging of cells and tissues

Country Status (3)

Country Link
EP (1) EP1501476A2 (en)
AU (1) AU2002232568A1 (en)
WO (1) WO2002047537A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2593964A1 (en) 2004-12-23 2006-06-29 Molmed Spa Conjugation product
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same

Also Published As

Publication number Publication date
EP1501476A2 (en) 2005-02-02
WO2002047537A2 (en) 2002-06-20
AU2002232568A1 (en) 2002-06-24

Similar Documents

Publication Publication Date Title
Massoud et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light
Carney et al. Non-invasive PET imaging of PARP1 expression in glioblastoma models
Weissleder Scaling down imaging: molecular mapping of cancer in mice
Lyons Advances in imaging mouse tumour models in vivo
Momcilovic et al. Imaging cancer metabolism
Alberti From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy
Zhou et al. Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice
Alford et al. Molecular probes for the in vivo imaging of cancer
WO2002081497A3 (en) αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE
Zhang et al. NIRF Optical/PET Dual‐Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye
Thorek et al. Molecular imaging using nanoparticle quenchers of Cerenkov luminescence
Lee et al. Magnetic resonance reporter gene imaging
Glasspool et al. Clinical imaging of cancer metastasis
Estorch et al. Future challenges of multimodality imaging
Cheng et al. Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications
Thakare et al. Functionalization of theranostic AGuIX® nanoparticles for PET/MRI/optical imaging
Vargas et al. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm
Zanzonico et al. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors
Ross et al. Magnetic resonance imaging in cancer research
Liu et al. Molecular imaging of cell-based cancer immunotherapy
Li et al. Development of a fibroblast activation protein-targeted PET/NIR dual-modality probe and its application in head and neck cancer
Munley et al. An introduction to molecular imaging in radiation oncology: A report by the AAPM Working Group on Molecular Imaging in Radiation Oncology (WGMIR)
McLendon et al. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis
Zhao et al. A handheld fluorescence molecular tomography system for intraoperative optical imaging of tumor margins
Allouche-Arnon et al. A Genetically Engineered Reporter System Designed for 2H-MRI Allows Quantitative In Vivo Mapping of Transgene Expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001992094

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001992094

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001992094

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)